These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 20061070

  • 1. Taurolidine lock is highly effective in preventing catheter-related bloodstream infections in patients on home parenteral nutrition: a heparin-controlled prospective trial.
    Bisseling TM, Willems MC, Versleijen MW, Hendriks JC, Vissers RK, Wanten GJ.
    Clin Nutr; 2010 Aug; 29(4):464-8. PubMed ID: 20061070
    [Abstract] [Full Text] [Related]

  • 2. Taurolidine lock - experience from the West of Scotland.
    Cullis PS, McKee RF.
    Clin Nutr; 2011 Jun; 30(3):399-400; author reply 401. PubMed ID: 21256637
    [No Abstract] [Full Text] [Related]

  • 3. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.
    Chu HP, Brind J, Tomar R, Hill S.
    J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):403-7. PubMed ID: 22595973
    [Abstract] [Full Text] [Related]

  • 4. Taurolidine in Pediatric Home Parenteral Nutrition Patients.
    Hulshof EC, Hanff LM, Olieman J, de Vette S, Driessen GJ, Meeussen C, Escher JC.
    Pediatr Infect Dis J; 2017 Feb; 36(2):233-235. PubMed ID: 27846059
    [Abstract] [Full Text] [Related]

  • 5. Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial.
    Klek S, Szczepanek K, Hermanowicz A, Galas A.
    JPEN J Parenter Enteral Nutr; 2015 Mar; 39(3):331-5. PubMed ID: 24604029
    [Abstract] [Full Text] [Related]

  • 6. Clinical and economic impact of the taurolidine lock on home parenteral nutrition.
    Arnoriaga Rodríguez M, Pérez de Ciriza Cordeu M, Camblor Álvarez M, Bretón Lesmes I, Motilla de la Cámara M, Velasco Gimeno C, Arhip L, García Peris P, Cuerda Compés C.
    Nutr Hosp; 2018 Jun 28; 35(4):761-766. PubMed ID: 30070861
    [Abstract] [Full Text] [Related]

  • 7. Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections.
    Jurewitsch B, Jeejeebhoy KN.
    Clin Nutr; 2005 Jun 28; 24(3):462-5. PubMed ID: 15896434
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
    Winnicki W, Herkner H, Lorenz M, Handisurya A, Kikić Ž, Bielesz B, Schairer B, Reiter T, Eskandary F, Sunder-Plassmann G, Sengoelge G.
    Kidney Int; 2018 Mar 28; 93(3):753-760. PubMed ID: 28890326
    [Abstract] [Full Text] [Related]

  • 13. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.
    Handrup MM, Møller JK, Schrøder H.
    Pediatr Blood Cancer; 2013 Aug 28; 60(8):1292-8. PubMed ID: 23417891
    [Abstract] [Full Text] [Related]

  • 14. Approaches to prolong the use of uncuffed hemodialysis catheters: results of a randomized trial.
    Filiopoulos V, Hadjiyannakos D, Koutis I, Trompouki S, Micha T, Lazarou D, Vlassopoulos D.
    Am J Nephrol; 2011 Aug 28; 33(3):260-8. PubMed ID: 21372561
    [Abstract] [Full Text] [Related]

  • 15. Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis.
    Solomon LR, Cheesbrough JS, Bhargava R, Mitsides N, Heap M, Green G, Diggle P.
    Semin Dial; 2012 Aug 28; 25(2):233-8. PubMed ID: 21916999
    [Abstract] [Full Text] [Related]

  • 16. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
    Betjes MG, van Agteren M.
    Nephrol Dial Transplant; 2004 Jun 28; 19(6):1546-51. PubMed ID: 14993498
    [Abstract] [Full Text] [Related]

  • 17. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.
    Dümichen MJ, Seeger K, Lode HN, Kühl JS, Ebell W, Degenhardt P, Singer M, Geffers C, Querfeld U.
    J Hosp Infect; 2012 Apr 28; 80(4):304-9. PubMed ID: 22342714
    [Abstract] [Full Text] [Related]

  • 18. Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections.
    Jurewitsch B, Lee T, Park J, Jeejeebhoy K.
    JPEN J Parenter Enteral Nutr; 1998 Apr 28; 22(4):242-4. PubMed ID: 9661127
    [Abstract] [Full Text] [Related]

  • 19. Taurolidine lock is superior to heparin lock in the prevention of catheter related bloodstream infections and occlusions.
    Olthof ED, Versleijen MW, Huisman-de Waal G, Feuth T, Kievit W, Wanten GJ.
    PLoS One; 2014 Apr 28; 9(11):e111216. PubMed ID: 25379781
    [Abstract] [Full Text] [Related]

  • 20. Do we know the benefits of a taurolidine lock in adult home parenteral nutrition patients with a low infection rate?
    Olthof ED, Broekman MM, Wanten GJ.
    JPEN J Parenter Enteral Nutr; 2015 May 28; 39(4):385. PubMed ID: 25883235
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.